Skip to main content

Table 2 Patient characteristics for diagnosed gout and asymptomatic hyperuricemia

From: Prevalence of gout and asymptomatic hyperuricemia in the pediatric population: a cross-sectional study of a Japanese health insurance database

  Total
(n = 276)
Age
0–5 years
(n = 22)
6–11 years
(n = 43)
12–18 years
(n = 211)
Age, years
 Median [Quartile] 15.0 [12.0, 17.0] 3.5 [2.0, 4.0] 9.0 [8.0, 11.0] 16.0 [14.0, 17.0]
Sex, n (%)
 Male 209 (75.7) 10 (45.5) 23 (53.5) 176 (83.4)
 Female 67 (24.3) 12 (54.5) 20 (46.5) 35 (16.6)
Comorbidity, n (%)
 Kidney disease 96 (34.8) 6 (27.3) 14 (32.6) 76 (36.0)
 Cardiovascular disease 63 (22.8) 9 (40.9) 15 (34.9) 39 (18.5)
 Metabolic syndrome 118 (42.8) 5 (22.7) 20 (46.5) 93 (44.1)
 Down syndrome 15 (5.4) 2 (9.1) 3 (7.0) 10 (4.7)
Treatment and drug use, n (%)
 Cardiovascular disease drug 9 (3.3) 0 (0.0) 5 (11.6) 4 (1.9)
 Diuretic drug 13 (4.7) 2 (9.1) 4 (9.3) 7 (3.3)
 β blocker 7 (2.5) 1 (4.5) 2 (4.7) 4 (1.9)
 Ca antagonist 8 (2.9) 0 (0.0) 1 (2.3) 7 (3.3)
 ACE inhibitor and/or ARB 32 (11.6) 1 (4.5) 6 (14.0) 25 (11.8)
 Antihyperlipidemic drug 14 (5.1) 0 (0.0) 0 (0.0) 14 (6.6)
 Antidiabetic drug 5 (1.8) 0 (0.0) 0 (0.0) 5 (2.4)
 Immunosuppressant 18 (6.5) 1 (4.5) 7 (16.3) 10 (4.7)
 Vitamin D 13 (4.7) 0 (0.0) 3 (7.0) 10 (4.7)
 Dialysis 2 (0.7) 0 (0.0) 0 (0.0) 2 (0.9)
 Treatment with uric acid lowering drug, n (%) 97 (35.1) 1 (4.5) 10 (23.3) 86 (40.8)
Number of measurement of sUA
 Median [Quartile] 2.0 [1.0, 4.0] 1.0 [0.0, 3.0] 3.0 [1.0, 6.0] 2.0 [1.0, 5.0]
Size of the facility, n (%)
 0–19 beds 113 (40.9) 3 (13.6) 11 (25.6) 99 (46.9)
 20–99 beds 6 (2.2) 1 (4.5) 0 (0.0) 5 (2.4)
 100–299 beds 31 (11.2) 2 (9.1) 4 (9.3) 25 (11.8)
  ≥ 300 beds 131 (47.5) 16 (72.7) 28 (65.1) 87 (41.2)
  1. ACE Angiotensin-converting enzyme, ARB Angiotensin II receptor blocker, sUA Serum uric acid